Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Ipsen Biopharmaceuticals, Inc.

Providing Patient-Centric Care in Pancreatic Cancer: Therapeutic Sequencing, Chemotherapy, and Novel Agents

Release Date: July 29, 2020
Expiration Date: July 29, 2021

Activity Overview

This online, on-demand virtual symposium brings together a renowned group of experts in the management of pancreatic adenocarcinoma who discuss current and emergent treatment strategies for this disease, with the goal of providing patient centered care. Experts in the management of pancreatic cancer discuss clinical trial evidence, informing guideline-based treatment approaches; placing these data sets in the context of evolving treatment standards in the field; the emerging role of maintenance therapy; differential toxicity considerations in multiple lines of care and the mitigation of adverse events; and novel therapeutic agents in clinical trials for advanced pancreatic cancer. The case-based format encourages sharing of best practices, evolving strategies, and clinical skills.

This educational activity is an archive of the live virtual symposium held on July 14, 2020.

Acknowledgement of Support

This activity is supported by educational grants from Celgene Corporation and Ipsen Biopharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists who treat pancreatic cancer. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with pancreatic cancer are also invited to attend.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Evaluate recent evidence regarding novel agents and approaches in treatment sequencing in pancreatic cancer.
  • Recommend appropriate therapeutic approaches across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics.
  • Identify patients with pancreatic cancer who are candidates for experimental therapy in ongoing clinical trials.
  • Integrate mitigation and management of treatment-related toxicities into clinical scenarios for patients with pancreatic cancer.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Shubham Pant, MD
Shubham Pant, MD
Associate Professor, Departments of Investigational Cancer Therapeutics and Gastrointestinal Medical Oncology
Associate Director, Department of Sheikh Ahmed Center for Early Phase Drug Development of Pancreatic Cancer Research
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Clinical trial: ArQule; Bristol Myers Squibb; Eli Lilly; Five Prime Therapeutics; GlaxoSmithKline; Mirati Therapeutics, Inc; Novartis; OncoResponse; Red Hill Biopharma Ltd; Rgenix; Sanofi-Aventis; Sanofi US Services Inc; Xencor; Consultant: Tyme, Xencor, Zymeworks.

Tanios Bekaii-Saab, MD, FACP
Tanios Bekaii-Saab, MD, FACP
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Vice-Chair and Section Lead, Division of Medical Oncology
Medical Director, Cancer Clinical Research Office
Senior Associate Consultant
Mayo Clinic
Phoenix, AZ

Disclosures: Grant Research Support: AbGenomics, Amgen, Array BioPharma, Bayer, Boston Biomedical, Bristol Myers Squibb, Celgene, Clovis, Genentech, Incyte, Ipsen, Lilly, Merck, Seattle Genetics; Consulting (to institution): Array Biopharma, Bayer, Genentech, Incyte, Ipsen, Merck, Seattle Genetics; Consulting (to self): Boehringer Ingelheim, Daiichi Sankyo, Eisai, Janssen, Natera, Sobi, Treos Bio; Other: IDMC/DSMB (to self): AstraZeneca, Exelixis, 1Globe, Lilly, Pancreatic Cancer Action Network Scientific advisory board: Immuneering, Imugene, Sun BioPharma Inventions/patents: WO/2018/183488 WO/2019/055687.

Andrew H. Ko, MD, FASCO
Andrew H. Ko, MD, FASCO
Professor and Interim Chief (Oncology), Division of Hematology/Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, CA

Disclosures: Grant Research Support: AbGenomics, Apexigen, Astellas (paid directly to my institution for support of clinical trials), Bristol Myers Squibb, Celgene, Roche/Genentech; Consultant: Data and safety monitoring committee members: Erytech, Imugene.

Eileen M. O’Reilly, MD
Eileen M. O’Reilly, MD
Winthrop Rockefeller Endowed Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary & Neuroendocrine Cancers
Codirector Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Disclosures: Grant Research Support: Research funding to Memorial Sloan Kettering Cancer Center: ActaBiologica, AstraZeneca, Bristol Myers Squibb, Celgene, Genentech, MabVax Therapeutics, Parker Institute, Roche; Consultant: Bayer, BioLineRx, Celgene, CytomX, Ipsen, Loxo, Merck, Polaris, Silenseed, Targovax.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
2728293031
Filter By